Diacerein: Recent insight into pharmacological activities and molecular pathways

Maged Almezgagi, Yu Zhang, Kamal Hezam, Emad Shamsan, Mohammed Gamah, Fadhl Al-shaebi, Abdul Baset Abbas, Muhammad Shoaib, Bassam Saif, Ying Han, Ruhan Jia, Wei Zhang

Research output: Contribution to journalReview articlepeer-review

61 Scopus citations

Abstract

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) and the active metabolite is rhein. It is a non-steroidal anti-inflammatory drug with unique pharmacological properties as anti-oxidant and anti-apoptosis. Diacerein has recently shown to have a potential role by mediating anti-inflammatory as well as anti-oxidant and anti-apoptosis in kidney injury, diabetes mullites, and a beneficial effect on pain relief. It may have a therapeutic role in cancer, ulcerative colitis, testicular injury and cervical hyperkeratosis. Furthermore, diacerein has a valuable addition in combination therapy as a synergetic agent. This review, the first of its kind, highlights the proposed roles of diacerein in osteoarthritis and discusses recent results supporting its emerging roles with a particular focus on how these new insights may facilitate the rational development of diacerein for targeted therapies in the future.

Original languageEnglish (US)
Article number110594
JournalBiomedicine and Pharmacotherapy
Volume131
DOIs
StatePublished - Nov 2020
Externally publishedYes

Keywords

  • Anti-apoptosis
  • Anti-inflammatory
  • Anti-oxidant
  • Cytokines
  • Diacerein

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Diacerein: Recent insight into pharmacological activities and molecular pathways'. Together they form a unique fingerprint.

Cite this